Clinical Trial Results:
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole with Lapatinib + Letrozole in Recurrent or Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Revised Protocol 02, incorporating Protocol Amendments 02 and 04
+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0 dated 20-Nov-09)
Summary
|
|
EudraCT number |
2009-016622-13 |
Trial protocol |
DE ES |
Global completion date |
16 Dec 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CA187-016_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.